Utility of HoxB13 in differential diagnosis of female genital tract lesions with putative prostatic differentiation

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61383082%3A_____%2F25%3A00001569" target="_blank" >RIV/61383082:_____/25:00001569 - isvavai.cz</a>

Výsledek na webu

<a href="https://pubmed.ncbi.nlm.nih.gov/41335140/" target="_blank" >https://pubmed.ncbi.nlm.nih.gov/41335140/</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s00428-025-04360-7" target="_blank" >10.1007/s00428-025-04360-7</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Utility of HoxB13 in differential diagnosis of female genital tract lesions with putative prostatic differentiation

Popis výsledku v původním jazyce

Female genital tract lesions with putative prostatic differentiation include vaginal tubulosquamous polyp (TSP), cervical ectopic prostatic tissue (EPT), and adenoid basal carcinoma (ABC). HoxB13 is a transcription factor specific for the prostate, not previously assessed in these lesions. A cohort of 13 TSPs, 6 EPTs, 17 ABCs, and 8 adenoid basal hyperplasia (ABH) was analyzed for expression of prostatic markers HoxB13, NKX3.1, p16, and androgen receptor (AR). Additional 28 cervical high-grade squamous intraepithelial lesions (HSILs), 21 cervical squamous cell carcinomas (SCCs), 19 endocervical adenocarcinomas (EACs), and 10 endometrial endometrioid adenocarcinomas (ECs) were included. The results were recorded as immunoreactive score (IRS). In TSPs and EPTs, HoxB13 and NKX3.1 were positive in 100% and 89.5% of cases, respectively. No HoxB13, NKX3.1, and p16 was observed in ABHs. In contrast, all ABCs showed diffuse p16 positivity. NKX3.1 was positive in 82.6% of ABCs (median IRS = 2), HoxB13 was positive in 100% of ABCs (median IRS = 8), and the difference was statistically significant (p < 0.001). Both HoxB13 and NKX3.1 were positive in 9.5% (2/21) SCCs and 21.1% (4/19) EACs. Additionally, 40% (4/10) ECs were HoxB13-positive (IRS = 1–2). Any positivity of HoxB13 was 80% specific and 100% sensitive for the ABC. NKX3.1 was only 82.4% sensitive, but 88% specific for the diagnosis of ABC. Additionally, HoxB13 was also seen in 29.8% HSILs. No ABC showed AR positivity, while this was observed in rare cells (IRS 1–2) in 30.8%, 16.6%, and 37.5% of TSCs, EPTs, and ABHs, respectively. HoxB13 can be a useful and reliable marker for identification of TSPs, EPTs and ABCs.

Název v anglickém jazyce

Utility of HoxB13 in differential diagnosis of female genital tract lesions with putative prostatic differentiation

Popis výsledku anglicky

Female genital tract lesions with putative prostatic differentiation include vaginal tubulosquamous polyp (TSP), cervical ectopic prostatic tissue (EPT), and adenoid basal carcinoma (ABC). HoxB13 is a transcription factor specific for the prostate, not previously assessed in these lesions. A cohort of 13 TSPs, 6 EPTs, 17 ABCs, and 8 adenoid basal hyperplasia (ABH) was analyzed for expression of prostatic markers HoxB13, NKX3.1, p16, and androgen receptor (AR). Additional 28 cervical high-grade squamous intraepithelial lesions (HSILs), 21 cervical squamous cell carcinomas (SCCs), 19 endocervical adenocarcinomas (EACs), and 10 endometrial endometrioid adenocarcinomas (ECs) were included. The results were recorded as immunoreactive score (IRS). In TSPs and EPTs, HoxB13 and NKX3.1 were positive in 100% and 89.5% of cases, respectively. No HoxB13, NKX3.1, and p16 was observed in ABHs. In contrast, all ABCs showed diffuse p16 positivity. NKX3.1 was positive in 82.6% of ABCs (median IRS = 2), HoxB13 was positive in 100% of ABCs (median IRS = 8), and the difference was statistically significant (p < 0.001). Both HoxB13 and NKX3.1 were positive in 9.5% (2/21) SCCs and 21.1% (4/19) EACs. Additionally, 40% (4/10) ECs were HoxB13-positive (IRS = 1–2). Any positivity of HoxB13 was 80% specific and 100% sensitive for the ABC. NKX3.1 was only 82.4% sensitive, but 88% specific for the diagnosis of ABC. Additionally, HoxB13 was also seen in 29.8% HSILs. No ABC showed AR positivity, while this was observed in rare cells (IRS 1–2) in 30.8%, 16.6%, and 37.5% of TSCs, EPTs, and ABHs, respectively. HoxB13 can be a useful and reliable marker for identification of TSPs, EPTs and ABCs.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30109 - Pathology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2025

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

VIRCHOWS ARCHIV

ISSN

0945-6317

e-ISSN

—

Svazek periodika

2025

Číslo periodika v rámci svazku

Dec

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

10

Strana od-do

1-10

Kód UT WoS článku

001634398900001

EID výsledku v databázi Scopus

2-s2.0-105023984960